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a b s t r a c t 
The previous research work in the literature for capacity planning and scheduling of biopharmaceutical 
manufacture focused mostly on the use of mixed integer linear programming (MILP). This paper presents 
fast genetic algorithm (GA) approaches for solving discrete-time MILP problems of capacity planning and 
scheduling in the biopharmaceutical industry. The proposed approach is validated on two case studies 
from the literature and compared with MILP models. In case study 1, a medium-term capacity planning 
problem of a single-site, multi-suite, multi-product biopharmaceutical manufacture is presented. The GA 
is shown to achieve the global optimum on average 3.6 times faster than a MILP model. In case study 
2, a larger long-term planning problem of multi-site, multi-product bio-manufacture is solved. Using the 
rolling horizon strategy, the GA is demonstrated to achieve near-optimal solutions (1% away from the 
global optimum) as fast as a MILP model. 
© 2018 The Authors. Published by Elsevier Ltd. 






































t  1. Introduction 
Biopharmaceutical drug development requires substantial in-
vestments of capital, human resources, and technological expertise.
The cost of development of a single drug entering human trials
between 1989 and 2002 was estimated to be in excess of $800M
( DiMasi et al., 2003 ). The development costs have been rising sub-
stantially for years. In an analysis by Paul et al. (2010) , the cost of
a new molecular entity was reported to be $1.8B. The likelihood of
a new biopharmaceutical drug product gaining approval for mar-
keting and the rate of approval for new products has been get-
ting lower over the years. According to Kaitin and DiMasi (2010) ,
only one in six new drugs that entered clinical trials in the United
States during 1993–98 and the 1999–2004 sub-periods were suc-
cessfully approved for marketing. Shanley (2014) reported that
only 12% of the candidate drugs get approved for use. Given the
high costs and the uncertainty of the biopharmaceutical devel-
opment process, building new capacity for products which may
or may not reach the market is not the most desirable option.
Therefore, it is essential to optimise the manufacturing capac-∗ Corresponding author. 
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0098-1354/© 2018 The Authors. Published by Elsevier Ltd. This is an open access article uty in an existing multi-product facility or a network of facilities.
ansohoff (2004) suggested that a typical mammalian cell-culture
acility could increase annual revenues by $380M with a 25% in-
rease in plant utilisation. 
Biopharmaceutical production planning is a complex combina-
orial optimisation problem complicated by the unique features
f biomanufacture. Biopharmaceutical companies typically have a
ortfolio of various products manufactured across a network of
wned and contract manufacturing facilities with wide-ranging
roduction capabilities. Biopharmaceutical products tend to be un-
table and thus have specialised and costly transportation and
torage requirements. Biopharmaceutical companies are also re-
uired to meet high-quality standards and prove they can deliver
 consistent manufacturing process. The high-quality standards are
chieved by rigorous cleaning and sterilisation between individual
roduction campaigns. 
The research work in the literature for capacity planning
nd scheduling of biopharmaceutical manufacture has focused on
iscrete-time MILP formulations adapted from the pharmaceu-
ical and chemical engineering industries ( Papageorgiou et al.,
001 ). The ﬁrst medium-term capacity planning model for a multi-
roduct, multi-suite biopharmaceutical facility was presented by
akhdar et al. (2005) . Their approach helped to determine the op-
imal durations and sequence of production campaigns togethernder the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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Indices 
i USP suites 
j DSP suites 
p products 
t, θ time periods 
Parameters 
H t available production time horizon over time period 
t , [days] 
C p USP storage capacity of product p, [batches] 
F p DSP storage capacity of product p, [batches] 
CR p USP production rate of product p, [batches/day] 
FR p DSP production rate of product p, [batches/day] 
CT min p min production time for product p in USP suite i , 
[days] 
CT max p max production time for product p in USP suite i, 
[days] 
F T min p min production time for product p in DSP suite j , 
[days] 
F T max p max production time for product p in DSP suite j, 
[days] 
αp USP lead time of product p, [days] 
βp DSP lead time of product p, [days] 
ρp USP storage cost, [RMU/batch] 
ω p DSP storage cost, [RMU/batch] 
ζ p USP shelf-life of product p, [time periods] 
σ p DSP shelf-life of product p, [time periods] 
λp production correspondence factor for USP to DSP 
production of product p 
ηp manufacturing cost, [RMU/batch] 
ψ p changeover cost, [RMU] 
T p waste disposal cost, [RMU/batch] 
νp sales prices, [RMU/batch] 
δp lateness penalty, [RMU/batch] 
D pt demand of product p at time period t, [batches] 
Integer variables 
product it part of the chromosome containing product labels 
allocated at time period t to USP suite i 
product jt part of the chromosome containing product labels 
allocated at time period t to DSP suite j 
time it part of the chromosome containing the number of 
production days allocated at time period t to USP 
suite i 
time jt part of the chromosome containing the number of 
production days allocated at time period t to DSP 
suite i 
B ipt number of batches of product p produced at time 
period t in USP suite i 
B jpt number of batches of product p produced at time 
period t in DSP suite j 
CI pt number of batches of USP product p stored at time 
period t 
FI pt number of batches of DSP product p stored at time 
period t 
CW pt number of batches of USP product p wasted at time 
period t 
FW pt number of batches of DSP product p wasted at time 
period t 
S pt number of batches of product p sold at time period 
t pt number of batches of product p in backlog at time 
period p 
Binary variables 
Y ipt 1 if product p is produced in USP suite i at time pe- 
riod t ; 0 otherwise 
Y jpt 1 if product p is produced in DSP suite j at time pe- 
riod t ; 0 otherwise 
Z ipt 1 if a new campaign of product p is produced in USP 
suite i at time period t ; 0 otherwise 
Z jpt 1 if a new campaign of product p is produced in DSP 
suite j at time period t ; 0 otherwise 
Continuous variables 
CT ipt production time for product p in USP suite i during 
time period t , [days] 
FT jpt production time for product p in DSP suite j during 
time period t , [days] 
Proﬁt total proﬁt – objective function, [RMU] 




t, θ , ξ time periods 
Sets 
PI i set of products that can be produced by facility i 
TI i set of time periods in which facility i is available 
Parameters 
H t available production time horizon over time period 
t , [days] 
C p storage capacity of product p, [kg] 
T min 
ip 




max production time for product p in facility i, 
[days] 
r ip production rate of product p at facility i, 
[batches/day] 
αip lead time for product p at facility i, [days] 
ζ p shelf-life of product p, [time periods] 
ηip manufacturing cost of product p at facility i , 
[RMU/batch] 
ρp storage cost of product p , [RMU/kg] 
ψ p changeover cost of product p , [RMU] 
νp sales prices, [RMU/kg] 
δp lateness penalty, [RMU/kg] 
ζ p shelf-life of product p, [time periods] 
πp backlog decay factor of product p 
yd ip yield conversion factor for product p in facility i, 
[kg/batch] 
D pt demand of product p at time period t, [kg] 
Integer variables 
product it part of the chromosome containing product labels 
allocated at time period t to facility i 
time it part of the chromosome containing the number of 
production days allocated at time period t to facility 
i 
B ipt number of batches of product p produced at time 
period t in facility i 













































































































t  Binary variables 
Y ipt 1 if product p is produced in facility i at time period 
t ; 0 otherwise 
Z ipt 1 if a new campaign of product p is produced in 
facility i at time period t ; 0 otherwise 
Continuous variables 
T ipt production time for product p at facility i during 
time period t , [days] 
K ipt amount of product p produced in facility i at time 
period t, [kg] 
I pt amount of product p stored at time period t, [kg] 
W pt amount of product p wasted in at time period t, [kg] 
S pt amount of product p sold at time period t, [kg] 
pt amount of product p in backlog at time period p, 
[kg] 
Proﬁt total proﬁt – objective function, [RMU] 
with product inventory, sales, and late deliveries proﬁles. Further-
more, the proposed MILP based optimisation method was shown
to ﬁnd more optimal solutions than the industrial rule-based ap-
proach. 
The randomness of the biopharmaceutical manufacturing en-
vironment can cause signiﬁcant scheduling and planning diﬃcul-
ties for the biopharmaceutical manufacturing campaigns. To ad-
dress this, Lakhdar and Papageorgiou (2006) applied MILP and
two-stage programming for medium-term planning of biopharma-
ceutical manufacture under uncertain fermentation titres. The pro-
posed methodology achieved better results than the deterministic
MILP model. 
The optimisation of biopharmaceutical manufacturing capacity
often involves many multiple conﬂicting criteria and objectives to
be considered. George et al. (2007) presented a multi-criteria de-
cision framework for the selection of strategies for acquiring bio-
pharmaceutical manufacturing capacity. Lakhdar et al. (2007) ad-
dressed the challenge of making long-term, multi-site capacity
planning decisions given multiple strategic criteria such as risk,
cost, and customer service levels. Using goal programming, they
developed a mathematical model that could optimise multiple ob-
jectives. 
The vast part of the research on biopharmaceutical manufacture
planning has been limited to either batch or fed-batch processes.
However, a more recent, large-scale discrete-time MILP model was
presented by Siganporia et al. (2014) to optimise long-term capac-
ity plans for a portfolio of biopharmaceutical products, with either
batch or perfusion bioprocesses, across multiple facilities to meet
quarterly demands. 
Genetic algorithms are stochastic, population-based search al-
gorithms that follow the naïve laws of evolution and natural selec-
tion. Unlike most other conventional optimisation algorithms, GAs
start from a pool of usually randomly generated solutions (also
known as chromosomes). Chromosomes with a higher objective
function value are selected for reproduction (crossover and muta-
tion) to generate new and hopefully better solutions for each new
iteration of the algorithm (also known as a generation). Since a
population of solutions is processed in each iteration of the GA,
the outcome is also a population of solutions. If an optimisation
problem has a global optimum, then all chromosomes can be ex-
pected to converge to it. Alternatively, if an optimisation prob-
lem has multiple optimal solutions, GAs can capture them in its
ﬁnal population ( Deb, 2001 ). Unlike classical optimisation meth-
ods which make assumptions about the relationships between the
variables, constraints, and the objective, GAs are ﬂexible optimisers
making minimal assumptions about the problem. Therefore, de-
spite the lack of guarantee of ﬁnding global optimum and the dif-culty of designing the objective function, chromosome structure,
nd operators, GAs have been used to obtain approximate solu-
ions to a wide range of complex linear and non-linear problem
uch as training neural networks ( Chen and Liao, 1998 ), ﬁnding
he optimal number, types, and positions of wireless transmitters
 Ting et al., 2009 ), and creating a program capable of solving plan-
ing problems described in Planning Domain Deﬁnition Language
PDDL) ( Brie and Morignot, 2005 ). 
At the time of writing, the literature on the use of alterna-
ive optimisation methods such as genetic algorithms (GAs) in
he biopharmaceutical industry was somewhat limited. Most of
he publications focused on the management of product portfolios
nd the optimisation of process design. On the portfolio manage-
ent front, George and Farid (2008) developed a stochastic, multi-
bjective optimisation framework based on probabilistic, model-
uilding genetic algorithms for the optimisation of the structure
nd development pathway of biopharmaceutical drug portfolios.
ie et al. (2012) presented a stochastic, GA-based decision-support
ool to address the decisions involved in portfolio management at
oth the drug development process level and the portfolio level.
n the process design front, Simaria et al. (2012) proposed a multi-
bjective GA-based approach for the selection and optimisation of
uriﬁcation sequences and chromatography column sizing strate-
ies. Allmendinger et al. (2012) presented a GA for the discovery
f chromatography equipment sizing strategies for antibody puriﬁ-
ation processes under uncertainty. 
The performance of the GA depends on its hyperparameter val-
es. For example, the rate of crossover controls the capability of
he GA in exploiting the known parts of the search space, whereas
he mutation rate controls the speed of the GA in exploring of
ew areas ( Lin et al., 2003 ). The values of these parameters are
uite often tuned one by one, i.e. by trial and error. However, this
an be a time consuming process leading to suboptimal results,
ince the interactions between the parameters are ignored this way
 Eiben et al., 1999 ). There has been a number of suggestions and
heoretical investigations into the optimal values of crossover, mu-
ation, and population size ( Back, 1993; Chipperﬁeld and Fleming,
995; Goldberg and Deb, 1991; Schaffer and Morishima, 1987 ). The
ypical values of crossover and mutation rate have been reported
o lie in the range 0.5–1.0 and 0.001–0.05 respectively. However,
ost investigations were based on simple function optimisation
roblems with traditional chromosome encoding strategies and ge-
etic operators. Therefore, their applicability for other types of
roblems and custom genetic operators is quite limited. An alter-
ative to manual parameter tuning is meta-optimisation, i.e. the
se of another optimisation algorithm to tune the GA hyperparam-
ters. For example, Grefenstette (1986) applied a meta-GA to op-
imise the hyperparameters of another GA. In this work, we use a
article swarm optimisation (PSO) algorithm to tune the GA. PSO is
n evolutionary, stochastic optimisation technique modelled after
warming and ﬂocking behaviours in animals, developed by James
ennedy and Russel Eberhart in the mid-1990s ( James and Rus-
ell, 1995; Luke, 2013 ). PSO is similar to a GA since it is also a
opulation-based algorithm. However, in PSO every solution is also
ssigned a randomised velocity vector and the potential solutions
re called particles. A more detailed description of PSO algorithm
an be found in an overview by Poli et al. (2007) . A PSO algorithm
as chosen due to its simplicity and relatively low computational
verhead (compared to using another GA) ( Pandey et al., 2010 ) and
uitability for the optimisation of functions with continuous inputs
 Hassan et al., 2004 ). 
This paper presents a fast GA-based approach to both medium-
nd long-term capacity planning and scheduling of single-
nd multi-site biopharmaceutical manufacture using discrete-time
odels. The proposed GA is demonstrated as a valid alternative
o MILP to obtain near-exact solutions to close to real-world in-
K. Jankauskas et al. / Computers and Chemical Engineering 121 (2019) 212–223 215 
Table 1 
The comparison of MILP model complexity between case 
study 1 and 2. 
Case Study 1 Case Study 2 
Single equations 535 19,430 
Single variables 457 25,018 
Discrete variables 252 9382 


























































(find optimal GA crossover and mutation values)
Genetic Algorithm
Capacity Planning Problem
(e.g. maximise operating profit)
Fig. 1. The meta-optimisation framework. Adapted from Camilleri et al. (2014) . 
Table 2 
Meta-optimisation parameters used in case study 1 and 2 to ﬁnd the GA optimal 
crossover and mutation parameter values. 
Case study 1 Case study 2 
PSO inertia weight, w 0.729 
PSO local weight, c 1 1.494 
PSO global weight, c 2 1.494 
PSO swarm size (number of particles) 20 
Number of PSO epochs 200 
Number of GA runs 100 50 

















 ustrial case studies of capacity planning and scheduling of bio-
harmaceutical manufacture. Other contributions of this paper in-
lude the chromosome encoding strategy, the algorithms describ-
ng the multi-suite and multi-site biopharmaceutical manufacture,
he rolling horizon approach for solving larger, long-term capacity
lanning problems, and a PSO-based meta-optimisation approach
or tuning the GA hyperparameters. 
The details of the proposed approach and two case studies are
utlined in Section 2 of this paper. Section 3 is dedicated to the
iscussion of the results and the comparison between the GA and
ILP. Conclusions and future work are provided in Section 4. 
. Methods 
In this section, the case studies of capacity planning and
cheduling of biopharmaceutical manufacture from two dif-
erent literature sources are described. In case study 1, a
edium-term capacity planning and scheduling problem of a
ulti-suite, multi-product biopharmaceutical manufacture from 
akhdar et al. (2005) is presented. In case study 2, a long-term
apacity planning and scheduling problem of multi-site, multi-
roduct bio-manufacture from Lakhdar et al. (2007) is solved. The
athematical models are summarised in the Appendix; however,
he reader is advised to refer to the original papers for a more in-
epth explanation. 
In this paper, the MILP models were recreated in GAMS 23.9.5
nd solved with a CPLEX 12.4.0.1 solver. GA and PSO algorithms
ere implemented using C ++ programming language. The imple-
entation of mathematical models using algebraic modelling sys-
ems such as GAMS is entirely different compared to the general-
urpose programming languages. GAMS allows the mathematical
odels to be implemented in a way that is very similar to their
athematical description, while the general-purpose programming
anguages require an explicit deﬁnition of every expression. An-
ther critical challenge of developing an eﬃcient GA-based ap-
roach was identifying the smallest number of independent vari-
bles and the shortest sequence of steps needed to evaluate the
andidate solutions for the case studies. 
In this section, the structure of the proposed approach and the
teps of the algorithms that captured capacity planning objectives
or multiple products across multiple suites and facilities are out-
ined. Most of the proposed GA-based approach is detailed in the
ethods section for case study 1. In case study 2, the focus is
laced on the rolling horizon strategy taken to improve the perfor-
ance of the standard GA for solving the long-term capacity plan-
ing problem. The relative complexity of the optimisation prob-
ems is illustrated by the summary of the MILP model statistics
hown in Table 1 . Both case studies were performed on an Intel
5-6500 based system with 16GB of RAM. 
The process of identifying the optimal parameters for an op-
imization algorithm or a machine learning one is usually costly
nvolves the search of a large, possibly inﬁnite, space of candidate
arameter sets, and may not guarantee optimality ( Camilleri et al.,
014 ). In this work, a simple PSO algorithm is implemented as a
eta-optimiser to automatically tune the crossover and mutation
arameter values in both case studies. Each particle, i.e. a potentialolution, is initiated with randomised position and velocity vec-
ors. A position vector holds the parameter values for the crossover
nd mutation. The ﬁtness of each particle is assessed by running
he GA using the parameter values from the position vector for a
peciﬁed number of independent algorithm runs with ﬁxed pop-
lation size and measuring the average of the best objective func-
ion values achieved. The concept of the meta-optimisation is illus-
rated in Fig. 1 . The parameter values of PSO algorithm ( Table 2 )
ere chosen based on the studies performed by Eberhart and
hi (20 0 0) and Trelea (20 03) . 
.1. Case study 1 – Medium-term capacity planning of a multi-suite, 
ulti-product biopharmaceutical facility 
The objective of the planning problem presented here is to
enerate a yearlong production schedule that would maximise
he manufacturing proﬁts. The problem statement adapted from
akhdar et al. (2005) is as follows: 
• Given: 
◦ Biopharmaceutical products P = {p1, p2, p3} 
◦ USP suites I = {i1, i2} and DSP suites J = {j1, j2} 
◦ A planning horizon of 360 days made of equal time periods 
T = {t1, t2, …, t6} 
◦ Product-dependent production rates, lead times, and pro-
duction throughputs (correspondence factors) 
◦ USP and DSP product shelf-life, storage capacities and costs 
◦ Product demands, sales price and backlog penalty costs 
◦ Manufacturing and campaign changeover costs 
◦ Minimum and maximum campaign durations 
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i1 (p, CTipt) (p, CTipt) (p, CTipt) (p, CTipt) (p, CTipt) (p, CTipt) … (p, CTipt) 
i2 (p, CTipt) (p, CTipt) (p, CTipt) (p, CTipt) (p, CTipt) (p, CTipt) … (p, CTipt) 
… … … … … … … … … 
in (p, CTipt) (p, CTipt) (p, CTipt) (p, CTipt) (p, CTipt) (p, CTipt) … (p, CTipt) 
Fig. 2. Chromosome encoding strategy for case study 1. Each “(p, CT ipt ) ” pair represents a gene with the information regarding which product p and how many days CT ipt 









































Case study 1 results and model statistics for 
MILP and GA models. 
MILP GA 
Max obj. function value 490 490 a 
Solution time (s) 0.22 0.07 b 
Optimality gap 0% 0% c 
Avg. obj. function value d – 490 ±0 
Population size – 100 
Crossover rate, pC e – 0.710 
Mutation rate, pM e – 0.070 
Termination f – 100 
a Max objective function value obtained from 
100 independent GA runs. 
b An average solution time of a single GA run. 
c An optimality estimate relative to the global 
optimal obtained using the recreated MILP 
model, i.e. 1 – obj. function value / global opti- 
mum. 
d Average of best objective function values 
from 100 independent GA runs (mean ±1 stan- 
dard deviation). 
e The parameter values were selected using 
the PSO algorithm. 
f If the best objective function value remained 
the same for 100 consecutive generations, the 






























u  • Determine: 
◦ Duration and sequence of campaigns 
◦ Production quantities along with inventory proﬁles 
◦ Product sales and late deliveries proﬁle 
• To: 
◦ Maximise manufacturing proﬁts 
2.1.1. Chromosome structure 
In both case study 1 and case study 2, the chromosomes use
the direct encoding of the key variables from the mathematical
models. Compared to the traditional form of binary encoding, e.g.
Holland (1975) , real-coded GAs have been shown to be more con-
sistent from run to run and provide faster, more precise perfor-
mance ( Gaffney et al., 2010; Janikow and Michalewicz, 1991 ). In
case study 1, each chromosome is an |I|-by-|T| array of tuples
where I is a set of USP suites, and T represents a set of discrete-
time periods (illustrated in Fig. 2 ). Each tuple comprises a product
label p and the length of production in USP suite i at time period
t, CT ipt , measured in days both of which are randomly generated at
the beginning of the GA. 
2.1.2. Genetic algorithm 
The GA comprises the following critical steps: ﬁtness evalua-
tion, tournament selection, reproduction (i.e. crossover and muta-
tion), and replacement. In case study 1, chromosomes for crossover
and mutation are selected using a binary tournament with replace-
ment strategy which favours individuals with a higher objective
function value, i.e. schedules with a larger proﬁt value. Tournament
selection has been shown to be computationally more eﬃcient and
have better or equivalent convergence when compared to other se-
lection methods that are available in the literature ( Goldberg and
Deb, 1991; Melanie, 1996 ). A uniform crossover operator with a
probability pC ( Table 3 ) is used to exchange the tuples between
the chromosomes. Each tuple is also mutated with a small prob-
ability pM ( Table 3 ) to avoid premature convergence and improve
the quality of the ﬁnal solution. During mutation, the product la-
bel is changed by replacing it with a random value from the set of
available products P. The length of production is varied by adding
or subtracting a random number of days, ensuring the allocated
campaign time is within the constrained range, CT min ip and CT 
max 
ip . 
In both case studies, the GA is augmented with elitism which is
a highly exploitative method of preserving the ﬁttest chromosomes
from the previous population ( Luke, 2013 ). In case study 1, a single
best chromosome is re-inserted into the population whenever it is
lost. Finally, the GA is set to terminate early if the ﬁtness of the
best individual has not improved for 100 consecutive generations. 
2.1.3. Fitness evaluation 
The ﬁtness evaluation procedures of case study 1 and case
study 2 are adapted from the MILP models ( Lakhdar et al., 2007,
2005 ) of multi-product biopharmaceutical manufacture. In case
study 1, the ﬁtness evaluation procedure generates a complete pro-
duction schedule which is used to estimate the objective function
value, i.e. proﬁt. The pseudo algorithm of the ﬁtness evaluation
procedure for case study 1 is presented in Table 4 . In Table 4 , Lines 3 and 4 retrieve the product label p and the
umber of production days allocated to USP suite i at time period t,
T ipt , from the chromosome which is an |I|-by-|T| array where I is a
et of upstream suites and T is a set of time periods. Lines 5 and 6
alculate the number of changeovers and batches produced in USP
uite i at time period t . In Line 5, the value of the changeover vari-
ble Z ipt will be equal to 1 only if product p has not been produced
n USP suite i at a previous time period t – 1. Line 7 accumulates
he production from all USP suites. Lines 9 and 10 estimate the
mount of product p wasted in USP suites at time period t which
s equal to the number of batches that was left unprocessed from
p periods ago. The amount of USP inventory of product p at time
eriod t is calculated in Line 11 by adding the cumulative value ob-
ained in Line 7 from time period t – 1 and subtracting the amount
f waste, CW pt . 
Line 13 ensures that the assignment of product p to DSP suite
 at time period t is performed only once. Lines 14 and 15 assign
roduct p to DSP suite j and calculate how many batches will be
roduced in that suite at time period t . This is performed by mul-
iplying the USP inventory value CI pt by the production correspon-
ence factor λp which speciﬁes the respective throughputs from
SP and DSP suites. For example, a factor of 0.5 signiﬁes that for
very two USP batches one DSP batch is produced. Line 15 eval-
ates the number of changeovers in DSP suites similarly to Line
. Line 16 checks whether the length of production of product p in
SP suite j at time period t does not exceed the allowed maximum.
f it does, the value of variable B jpt is iteratively decremented until
he production time FT jpt is below or equal the value of the con-
traint, F T max p . Line 17 updates the value of USP inventory of prod-
ct p at time period t by subtracting the number of batches that
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Table 4 
Pseudocode for ﬁtness evaluation in case study 1. 
1 for each time period t 24 if t > σ p 
2 for each upstream suite i 25 FW pt = FI p,t- σp-1 − ( 
∑ σp 
θ= t−σp S pθ + 
∑ σp 
θ= t−σp F W pθ ) 
3 p = products it 26 FI pt = FI pt + FI p,t-1 − FW pt 
4 CT ipt = time it 27 if D pt > 0 
5 Z ipt = 1 − (t > 0 and p == products i,t-1 ) 28 if D pt ≤ FI pt 
6 B ipt = Z ipt + CR p (CT ipt −αp Z ipt ) 29 S pt = D pt 
7 CI pt = CI pt + B ipt 30 FI pt = FI pt − S pt 
8 for each product p 31 else 
9 if t > ζ p 32 S pt = FI pt 




θ= t−ζp B jpθ + 
∑ ζp 
θ= t−ζp C W pθ ) 33 FI pt = 0 
11 CI pt = CI pt + CI p,t-1 −CW pt 34 pt = D pt − S pt 
12 for each downstream suite j 35 if p,t- 1 > 0 
13 if products jt = = 0 36 if p,t- 1 ≤ FI pt 
14 B jpt = λp CI pt 37 S pt = S pt + p,t-1 
15 Z jpt = 1 − (t > 0 and p == products j,t-1 ) 38 FI pt = FI pt −p,t-1 
16 while ( F T ipt = βp Z jpt + B jpt −Z jpt F R p ) > F T 
max 
p do B jpt = B jpt − 1 39 else 
17 C I pt = C I pt − B jpt λp 40 S pt = S pt + FI pt 
18 FI pt = FI pt + B jpt 41 FI pt = 0 
19 products jt = p 42 pt = pt + p,t-1 − S pt 
20 time jt = FT jpt 43 if FI pt > F p 
21 if CI pt > C p 44 FW pt = FW pt + FI pt − F p 
22 CW pt = CW pt + CI pt −C p 45 FI pt = F p 
























































t  re processed in DSP suite j. Line 18 accumulates the production
rom all DSP suites. Lines 19 and 20 assign the product p and DSP
roduction time FT jpt to the DSP part of the chromosome. Lines 21–
3 ensure that the levels of USP inventory do not exceed the stor-
ge limit. Any excess inventory of product p during time period t
s calculated as waste, CW pt . 
The amount of DSP waste, FW pt , and inventory levels of product
 at time period t , FI pt , are calculated in Lines 24–26 similarly to
ines 9–11. In Line 27, if there is a demand, D pt , for product p at
ime period t , then the amount of product sold, S pt , is calculated
ased on the number of batches stored in DSP inventory FI pt . If
here are more batches in storage than there are in demand (Line
8), the variable S pt will be equal to the value of demand (Line 29).
therwise, Line 32 assigns the value of DSP storage FI pt to S pt , and
he backlog is recorded using variable pt for that time period in
ine 34. If the inventory allows it, the backlog from a previous time
eriod p,t-1 is sold in Lines 35–41. Otherwise, it is accumulated in
ine 42. Lines 43–45 ensure that DSP storage capacity, F p , is not
xceeded by discarding any extra, unsold batches. 
The ﬁtness of each chromosome is assessed by calculating the
roﬁt achieved by the schedule using the same objective function
1) as presented by Lakhdar et al. (2005) . The objective function
alue is equal to the difference between the total sales and the
osts of manufacturing, product changeovers, intermediate and ﬁ-
al product storage, waste disposal, and late deliveries. 






νp S pt −
∑ 
i 
ηp B ipt −
∑ 
i 
ψ p Z ipt −
∑ 
j 




ψ p Z jpt −ρp CI pt −ω p F I pt −δp pt −τp 
(
CW pt + F W pt 
)) 
(1) 
.2. Case study 2 – Long-term capacity planning and scheduling 
roblem of multi-site, multi-product bio-manufacture 
The goal of the planning problem presented in this case study is
o generate a 15-yearlong production schedule to maximise manu-
acturing proﬁts. The problems presented here is a single-objective
roblem adapted from Lakhdar et al. (2007) . The following is a
roblem statement: ● Given: 
◦ A network of multi-product facilities I = {i1, i2, …, i15} 
◦ Biopharmaceutical products P = {p1, p2, …, p10} 
◦ A planning horizon of 15 years with equal time periods 
T = {t1, t2, …, t60} 
◦ Production rates, yields, and lead times 
◦ Product lifetimes and storage capacities 
◦ Product demands and sales prices 
◦ Backlog decay factor 
◦ Manufacturing, changeover, storage costs, and late delivery
penalties 
◦ Minimum and maximum campaign durations 
● Determine: 
◦ Campaign durations and sequence of campaigns 
◦ Production quantities along with inventory proﬁles 
◦ Product sales and late deliveries proﬁle 
● To: 
◦ Maximise manufacturing proﬁts 
In their paper, Lakhdar et al. (2007) stated that the presented
ILP model was an extension of the one already discussed in case
tudy 1 of this paper. The core mathematical formulation for the
ingle-objective problem remained mostly the same with the only
ost noticeable change being the lack of the explicit model of sep-
rate USP and DSP suites. Nevertheless, the complexity of the prob-
em in case study 2 is much higher compared to case study 1 due
o a greater number of products, facilities, and time periods. Each
ndividual time period t is limited to a maximum of 87 days com-
ared to 60 in case study 1, and there are 10 products which need
o be allocated to 15 facilities. Additional subsets are introduced to
eﬁne facility availability and manufacturing capability: PI i , the set
f products that can be manufactured in facility i , and TI i , the set
f time periods during which facility i is available for use. Further-
ore, the production yield, as well as manufacturing costs of each
roduct p, also depend on the facility i it is being manufactured in.
.2.1. Chromosome structure 
The increased complexity of the planning problem in case study
 presented a challenge for the GA-based approach. Encoding the
hromosomes as full-scale |I|-by-|T| arrays was found to be com-
utationally costly. A rolling horizon method was taken to explore
he large search space in a more eﬃcient manner by dividing the
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Table 5 
Pseudocode for the dynamic GA in case study 2. 
1 for each subproblem 
2 parents = GeneratePopulation() 
3 EvaluateFitness(parents) 
4 subproblem_best = max(parents) 
5 gen = 0, not_restarted = true 
6 while gen < max_gens 
7 offspring = Select(parents) 
8 Reproduce(offspring, pC, pMutP, pMutT) 
9 EvaluateFitness(offspring) 
10 Replace(parents, offspring) 
11 current best = max(parents) 
12 if current_best > subproblem_best 
13 subproblem best = current_best 
14 if subproblem_best = = subproblem_best from 20 generations ago 
15 if not_restarted 
16 parents = RestartSubproblem() 
17 not_restarted = false 
18 else 
19 break 









































Fig. 3. An illustration of how the long-term capacity planning problem from case 
study 2 can be divided into smaller sub-problems. The full solution and each sub- 
problem (Year n) are |I|-by-|T| and |I|-by-|T| arrays respectively. The sub-problems 
overlap with one another on the parts that are shaded in grey. 15-yearlong planning problem into 15 equal sub-problems which
were solved consecutively. In order to accomplish this, each chro-
mosome encoded a sub-problem as an |I|-by-|T| array of product p
and the length of production, T ipt , values where T ⊂ T and |T| = 4. T
represents the extent of the rolling horizon, i.e. a dynamic subset
of 4 time periods which correspond to the timeline of the sub-
problem being solved. For example, T = {t1, t2, t3, t4} and T = {t57,
t58, t59, t60} contain the time periods for the ﬁrst and last sub-
problems, respectively. The best solution from each sub-problem
is stored in the ﬁnal, full-scale |I|-by-|T| solution, before proceed-
ing to solve the following sub-problem. The values of the variables
corresponding to the best solution such as the number of batches
of product p produced in each facility i during time period t, B ipt ,
are ﬁxed so they would not need to be recalculated for the next
sub-problem. To distinguish the rolling horizon approach-based GA
from the standard one, it will be referred to it as the dynamic GA.
The concept of the dynamic GA is illustrated in Fig. 3. The pseudo-
algorithm for the dynamic GA is listed in Table 5 . 
A new parent population is generated for every sub-problem
with the values of product p for each facility i selected randomly
from the set of allowable products for that facility, PI i , making sure
the facility i is also available for use at time period t ∈ TI i . A prod-
uct label with a value of 0 is also included in the set to denote an
idle state of the facility i during a time period t when no product
is being manufactured. 
2.2.2. Genetic algorithm 
A uniform crossover operator with a probability pC ( Table 6 )
is used to create two offspring from two parent chromosomes. T
noise into the system, the mutation of the values of p and T is
made independent, i.e. the probabilities pMutP and pMutT ( Table 6 )
associated with each step are independent of one another. Pro-
vided that the facility i is available for use at time period t , the
value of product label p is mutated by assigning 0 or a random
value from the subset PI i . The value of T ipt is mutated by adding
or subtracting a random number of days, ensuring the allowable
range for T ipt is not exceeded. 
The parent population of gen + 1 is made up of the recombined
and mutated offspring. If no better solutions are found, then the
top 5% of the previous parent population replace the worst per-
formers of the latest generation. A completely new parent popula-
tion is generated when the best ﬁtness value remains unchanged
for a speciﬁed number of consecutive generations (Lines 14–16,
Table 5 ) and the previous top 5% chromosomes are added. When
K. Jankauskas et al. / Computers and Chemical Engineering 121 (2019) 212–223 219 
Table 6 
Case study 2 results and model statistics for MILP and GA models. 
MILP GA 
Global optimum Relaxed Dynamic Standard 
Max obj. function value 66,360 65,940 65,849 a 61,880 a 
Time (s) 10 0 0.36 8.77 8.09 b 21.56 b 
Optimality gap 0% 0.6% 0.8% c 6.8% c 
Avg. obj. function value d – 65,652 ±112 61,186 ±437 
Population size – 200 200 
Crossover rate, pC e – 0.686 0.597 
Mutation rate, pMutP e – 0.004 0.001 
Mutation rate, pMutT e – 0.295 0.295 
Elitism – 5% 5% 
Termination – 25 f 10 0 0 g 
a Max obj. function value obtained from 50 independent GA runs. 
b An average solution time of a single GA run. 
c An optimality estimate relative to the global optimum obtained using the recreated MILP 
model, i.e. 1 – obj. function value / global optimum. 
d Average of best objective function values from 50 independent GA runs (mean ±1 stan- 
dard deviation) 
e The parameter values were selected using the PSO algorithm. 
f If the best objective function value remained unchanged for 25 consecutive generations, 
the GA was restarted with a new parent population. The second time the best objective 
function value stayed the same for the same number of generations, the GA was terminated. 
g Terminated after 10 0 0 generations had elapsed irrespective of the best objective function 
value achieved. 
Table 7 
Case study 2 results and model statistics for the dynamic GA model using different early stopping values and 
population sizes. 
Avg. obj. function value a Max obj. function value b Avg. solution time Population size Termination c 
65,399 ±131 65,653 3.91 s 100 25 
65,518 ±144 65,799 6.11 s 100 50 
65,543 ±144 65,818 8.30 s 100 75 
65,652 ±112 65,849 8.09 s 200 25 
65,755 ±105 65,934 12.87 s 200 50 
65,797 ±92 65,987 17.20 s 200 75 
65,806 ±66 65,921 12.66 s 300 25 
65,855 ±86 65,997 19.86 s 300 50 
65,883 ±92 66,068 26.85 s 300 75 
a Average of best objective function values from 50 independent GA runs (mean ±1 standard deviation). 
b Max objective function value obtained from 50 independent GA runs. 
c If the best objective function value remains unchanged for a given number of consecutive generations, the GA 
is restarted with a new parent population. The second time the best objective function value stays the same for 
the same number of generations, the GA is terminated. 
Table 8 
Pseudocode for ﬁtness evaluation in case study 2. 
1 ξ = 0 15 if D pt > 0 
2 for each time period t in sub_problem 16 if D pt ≤ I pt 
3 for each facility i 17 S pt = D pt 
4 p = products i ξ 18 I pt = I pt − S pt 
5 T ipt = time i ξ 19 else 
6 Z ipt = 1 − (t > 0 and B ip,t- 1 = = 0) 20 S pt = I pt 
7 B ipt = Z ipt + r ip (T ipt −αp Z ipt ) 21 I pt = 0 
8 K ipt = B ipt yd ip 22 pt = D pt − S pt 
9 I pt = I pt + K ipt 23 if p,t- 1 ≥ 0 
10 ξ = ξ + 1 24 if p,t- 1 ≤ I pt 
11 for each product p 25 S pt = S pt + p,t-1 
12 if t > ζ p 26 I pt = I pt −p,t −1 
13 W pt = I p,t- ζp-1 − ( 
∑ ζp 
θ= t−ζp S pθ+ 
∑ ζp 
θ= t−ζp W pθ ) 27 else 
14 I pt = I pt + I ip,t −1 −W pt 28 S pt = S pt + I pt 
29 I pt = 0 








p  his repeats, the best sub-problem is added to the full solution, and
 new sub-problem is started (Lines 14, 17–20, Table 5 ). We tested
erminating the GA after 25, 50, and 75 generations with popula-
ion sizes of 100, 200, and 300 chromosomes ( Table 7 ). c  
v  
b  .2.3. Fitness evaluation 
In Table 8 , the variable ξ is used to iterate through the val-
es of the |I|-by-|T| array contained within each chromosome . The
roduct label p and production length T ipt are retrieved from the
hromosomes in Lines 4 and 5 . The value of the binary changeover
ariable Z ipt is set to 1 in Line 6 if variable B ip,t -1 , the number of
atches of product p produced in facility i in the previous time
















































Fig. 4. Production schedule for case study 1 with an objective function value of 490 
RMU and 0% optimality gap. Both the MILP model and the proposed GA generated 
the same schedule. The ﬁrst number in each cell denotes the number of batches 
produced which is followed by the production time [days] in brackets. The shading 
















































a  period slot, is 0. The value of the number of batches variable B ipt 
during time period t is calculated in Line 7 and converted into
kilograms K ipt using the yield conversion factor yd ip in Line 8. The
value of yd ip depends the facility i which the product p is being
manufactured in. Line 9 accumulates the value of K ipt into the vari-
able I pt – the amount of product p in kilograms stored at time pe-
riod t. The amount of product waste W pt is estimated in Line 12
and 13. The value of this variable is equal to the amount of prod-
uct p that was not sold and remained in storage for more than ζ p 
time periods. The rest of the pseudocode in Table 8 (from Line 14
and onwards) is nearly identical to the Lines 27-45 from the pseu-
docode for the ﬁtness evaluation in case study 1 ( Table 3 ). The only
notable differences are the lack of storage capacity constraint and
the addition of backlog decay factor π which diminishes the im-
portance of the backlogged orders during the ﬁtness evaluation in
case study 2. 
The ﬁtness of each chromosome is evaluated using the
objective function of proﬁt maximisation (2) deﬁned by
Lakhdar et al. (2007) . The objective function value is equal to
the difference between the total sales, with each batch sold at a
price νp , and the total operating costs which include the costs of





t∈ T I i 
( 
νp S pt − ρp I pt − δp pt 
−
∑ 
i ∈ IP i 
(
ηp B ipt + ψ p Z ipt 
)) 
(2)
3. Results and Discussion 
In this section, the results to the case studies of capacity plan-
ning and scheduling of biomanufacture from the literature are pre-
sented. In case study 1, the problem consists of a multi-suite facil-
ity, with 2 USP ( I = {i 1 , i 2 } ) and 2 DSP ( J = {j 1 , j 2 } ) suites to produce
3 products ( P = {p 1 , p 2 , p 3 } ) with multiple intermediate demand
dates due during a 360-day long production time horizon. The
horizon is discretised into 6 time periods ( T = {t 1 , t 2 , …, t 6 } ) of 60
days. In case study 2, the problem consists of 10 facilities ( I = {i 1 ,
i 2 , …, i 10 } ) with different manufacturing capabilities PI i (subset of
facilities capable of producing product p ) and availability TI i (sub-
set of facilities available at time period t ) to produce 15 products
( P = {p 1 , p 2 , …, p 15 } ) due annually during a 15-yearlong produc-
tion time horizon. The horizon consists of 60 discrete time periods
( T = {t 1 , t 2 , …, t 60 } ) of 87 days. 
The GAs discussed in the previous sections for case study 1 and
case study 2 are used to solve the respective scheduling problems,
and the results are compared with the recreated MILP models (see
Tables 3 and 6 ). A comparison between the production schedules
generated using MILP, and a GA is also provided in Figs. 4 and 5 .
The reader is advised to refer to the original papers ( Lakhdar et al.,
20 07, 20 05 ) for the input data used. 
3.1. Case study 1 results 
The proposed GA developed in this research was ﬁrst applied
to case study 1 on medium-term capacity planning for a single-
site, multi-suite, multi-product biopharmaceutical facility. Initially,
a MILP model was developed for the problem as a benchmark
for comparison with the GA performance. In their original MILP
work, Lakhdar et al. (2005) reported an objective function value of
487 relative monetary units (RMU) with a 5% optimality gap for
this problem, while using the reproduced MILP model an objective
function value of 490 RMU was achieved with 0% optimality gap
indicating a global optimum. The proposed PSO-based meta-optimisation approach was used
o tune the crossover and mutation parameter values, pC and
M . Using this approach, the optimal values of crossover rate
 pC = 0.710 ) and mutation rate ( pM = 0.070 ) were identiﬁed, and
he GA achieved the global optimum of 490 RMU for 100 consecu-
ive, independent algorithm runs. The GA also generated a produc-
ion schedule with the product allocation pattern identical to the
ne from the recreated MILP model ( Fig. 4 ). The average solution
ime of the GA was 0.07 s compared to MILP which took an aver-
ge of 0.22 s to ﬁnd the global optimum (the MILP model was run
0 times to evaluate the running time). 
Given the fast performance of the proposed GA-based method
nd the optimality of the results, it can be considered as a vi-
ble alternative for addressing medium-term capacity planning and
cheduling problems similar in structure and complexity to case
tudy 1. 
.2. Case study 2 results 
Having tackled medium-term, single-site facility scheduling, the
A was then extended to address long-term planning across multi-
ite, multi-product biopharmaceutical manufacturing facilities in
ase study 2. To set the benchmark for the GA, the recreated
ingle-objective MILP model was used to achieve an objective func-
ion value of 66,360 RMU with a 0% optimality gap for this prob-
em. It took approximately 16.7 min to ﬁnd the global optimum.
ith the optimality gap increased to 1%, the MILP model achieved
n objective function value of 65,940 RMU in 8.77 s. 
As discussed earlier, two versions of a GA ( standard and dy-
amic ) were applied to solve the long-term capacity planning
roblem presented in case study 2. Using the standard version,
ach chromosome encoded the full-scale problem as an |I|-by-|T|
rray (where | I| = 10 and |T| = 60), and the GA was set to termi-
ate after 10 0 0 generations had elapsed. In the dynamic version, a
olling horizon approach was utilised to break down the full-scale
5-yearlong scheduling problem into 15 sub-problems. Each chro-
osome encoded only a part of the full schedule as an |I|-by-|T|
rray (where T ∈ T and |T| = 4 ) corresponding to the sub-problem
eing solved. Additionally, the dynamic GA was restarted once the
tness value remained unchanged for a set number of consecutive
enerations. The crossover, mutation and elitism steps were iden-
ical in both standard and dynamic versions. 
The comparison of the results between the MILP and GA is
ummarised in Table 6 . For a fair comparison, the PSO-based meta-
ptimisation was applied to tune both GA versions. After 50 runs,
he average best objective function value using the standard GA
as 61,186 ±437 while the dynamic GA achieved 65,652 ±112 . Ad-
itionally , the solution time of the dynamic GA was approximately
.7 times faster than that of the standard version (8.09 s vs 21.56 s)
nd slightly faster than that of the relaxed MILP model (8.09 s vs
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Fig. 5. Production schedules for case study 2. Each product p n (where n = 1, 2, …, 15) is denoted by a colour label displayed in the legend below the schedules. The numbers 
of batches of each product produced have been removed for clarity purposes. 
A) Generated using the MILP model. An objective function value of 65,940 RMU was obtained with 0.6% optimality margin (based on the known global optimum as the 
upper bound). 


































































U  .77 s). Using the known global optimum of 66,360 RMU as an up-
er bound, the average and the lowest optimality gaps achieved
sing the dynamic GA were estimated to be 1.0% and 0.8%, respec-
ively. In comparison, the relaxed MILP model returned an objec-
ive function value of 65,940 with a 0.6% optimality gap 
The pattern of the most proﬁtable production schedule pro-
uced by the dynamic GA ( Fig. 5 B) holds a close resemblance to
he MILP-generated one ( Fig. 5 A), for example: 
• Facilities i 1 and i 2 run with little to no idle time and with a
variety of different products allocated to them. 
• Facility i 3 is busier in the ﬁrst half of the scheduling table with
more product allocations. 
• Product p 4 is almost exclusively produced in the facility i 4 . 
• Facility i 4 has no idle time periods. 
• Certain facilities such as i 5 and i 10 are completely idle. 
Nevertheless, the production schedule generated with MILP is
ore systematic and has more products allocated overall. For ex-
mple, in Fig. 5 A, the product allocation in the facility i 8 is more
onsistent than in Fig. 5 B, in which the production is scheduled as
ate as possible thus saving storage costs. 
. Conclusions 
In this work, novel GA-based optimisation approaches were de-
eloped for medium and long-term, discrete-time, mixed-integer
apacity planning models of biopharmaceutical manufacture. The
ey enabling features of the GA-based approaches included a
hromosome encoding strategy, a dynamic, rolling horizon ap-
roach to improving the performance of the GA for tackling the
ong-term capacity planning and scheduling problem, and algo-
ithms that captured capacity planning objectives for multiple
roducts across multiple suites and facilities. A PSO-based meta-
ptimisation method was also presented for automatic tuning of
rossover and mutation parameter values as an alternative to man-
al tuning. The feasibility of the novel GA-based optimisation algo-
ithms was demonstrated on two case studies from the literature. 
In case study 1, a medium-term capacity planning problem of
 single-site, multi-suite biopharmaceutical facility was solved. Theroposed GA obtained the global optimum with less CPU time than
 MILP model. 
In case study 2, a more computationally complex, long-term ca-
acity planning problem of a multi-site biopharmaceutical manu-
acture was solved. Using the rolling horizon approach, the full-
cale problem was divided into 15 sub-problems which were
olved consecutively. Based on the known global optimum, the av-
rage optimality gap of the solution generated using the dynamic
A was 1.0%. 
In this paper, the GA-based approaches were demonstrated to
e capable of achieving the exact or very similar performance com-
ared to MILP in terms of the objective function optimality and
peed. This paper serves as a starting point for tackling even more
omplex capacity planning and scheduling problems of biophar-
aceutical manufacture using GA-based approaches. In the future,
he work presented in this paper could be extended to address
tochastic planning problems with uncertain parameters, e.g. fer-
entation titres or product demand, as well as multi-objective
roblems. 
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ppendix A 
This appendix summarises the mathematical model presented
y Lakhdar et al. (2005) . 
roduction constraints 
Constraints 1 and 2 represent the manufacture of product in
SP and DSP suites. Upstream production, B ipt , and downstream













































































iproduction, B jpt , are represented by continuous rates of produc-
tion, CR p and FR p , which are combined with their respective USP
and DSP lead times, αp and βp , and USP and DSP production times,
CT ipt and FT jpt . Constraints 3 and 4 activate lead time in USP suite
i and DSP suite j if the same product p has not been manufactured
in the preceding time period, t – 1. Constraints 5 and 6 ensures
that only one product p is produced in any USP suite i and DSP
suite j at any time period t . 
B ipt = Z ipt + C R p 
(
C T ipt − αp Z ipt 
) ∀ i, p, t (1)
B jpt = Z jpt + F R p 
(
F T jpt − βp Z jpt 
) ∀ j, p, t (2)
Z ipt ≥ Y ipt − Y ip,t−1 ∀ i, p, t (3)
Z jpt ≥ Y jpt − Y jp,t−1 ∀ j, p, t (4)
∑ 
p 
Y ipt ≤ 1 ∀ i, t (5)
∑ 
p 
Y jpt ≤ 1 ∀ j, t (6)
Timing constraints 
Constraints 7 and 8 represent the appropriate minimum and
maximum production times for USP and DSP suites, which are only
activated when Y ipt and Y jpt are equal to 1. Constraints 9 and 10 en-
sure that the total USP or DSP time does not exceed the speciﬁed
production time horizon, H t . 
 T min p Y ipt ≤ C T ipt ≤ C T max p Y ipt ∀ i, p, t (7)
F T min p Y jpt ≤ F T jpt ≤ F T max p Y jpt ∀ j, p, t (8)
∑ 
p 
C T ipt ≤ H t ∀ i, t (9)
∑ 
p 
F T jpt ≤ H t ∀ j, t (10)
Storage constraints 
Constraints 11 and 12 enforce an inventory balance in upstream
and downstream production and force the total downstream pro-
duction to meet the product demand. Constraints 13 and 14 ensure
that the amount of upstream and downstream product stored over
timer period t is positive and below the maximum available stor-
age capacities, C p and F p . Both upstream and downstream prod-
uct inventory is constrained by the limited product shelf-life. Con-
straints 15 and 16 ensure the total amount of stored upstream
product and downstream product is used after the next ζ p or σ p 
time periods, respectively. 








B jpt −C W pt ∀ p, t (11)
F I pt = F I p,t−1 + 
∑ 
j 
B jpt − S pt − F W pt ∀ p, t (12)
0 ≤ C I pt ≤ C p ∀ p, t (13)
0 ≤ F I pt ≤ F p ∀ p, t (14)
 I pt ≤
∑ 
j 
∑ t+ ζp 
θ= t+1 B jpθ ∀ p, t (15)
F I ≤
∑ t+ σp 
S ∀ p, t (16)pt 
θ= t+1 pθ I  acklog constraints 
Constraint 17 penalises the amount of product p that was late
or delivery at time period t, pt . 
pt = p, t−1 + D pt − S pt ∀ p, t (17)
bjective function 
The objective function is to maximise proﬁt which is equal to
he difference between total sales and total operating costs. All
osts and prices are in relative monetary units (RMU). 





( νp S pt −
∑ 
i 
ηp B ipt −
∑ 
i 







ψ p Z jpt − ρp C I pt − ω p F I pt − δp pt 
− τp (C W pt + F W pt )) (18
ppendix B 
This appendix summarises the mathematical model presented
y Lakhdar et al. (2007) . 
roduction constraints 
Constraint 1 represents biopharmaceutical production. The
umber of batches produced in facility i of product p at time pe-
iod t, B ipt , is represented by a continuous production rate, r ip , pro-
uction lead time, αip , and production time T ipt . Constraint 2 con-
erts the integer number of batches , B ipt , into kilograms, K ipt , us-
ng a yield conversion factor , yd ip . Constraint 3 activates lead time
n facility i if the same product p has not been manufactured in
he preceding time period, t −1. Constraint 4 ensures that only one
roduct p is produced in any facility i at any time period t . 
 ipt = Z ipt + r pt 
(
T ipt − αip Z ipt 
) ∀ i, p ∈ P I i , t ∈ T I i (1)
 ipt = B ipt y d ip ∀ i, p ∈ P I i , t ∈ T I i (2)
 ipt ≥ Y ipt − Y ip,t−1 ∀ i, p ∈ P I i , t ∈ T I i (3)
 
p∈ P I i 
Y ipt ≤ 1 ∀ i, t ∈ T I i (4)
iming constraints 
Constraints 5 and 6 represent the appropriate minimum and
aximum campaign durations, T min 
ip 
and T max 
ip 
, which are only acti-
ated when Y ipt is equal to 1. 
 
min 
ip Y ipt ≤ T ipt ∀ i, p ∈ P I i , t ∈ T I i (5)
 ipt ≤ min 
{
T max ip , H t 
}
Y ipt ∀ i, p ∈ P I i , t ∈ T I i (6)
torage xonstraints 
Constraint 7 enforces inventory balance for production and
orces the total production to meet the product demand. Constraint
 enforces that the amount of product p in inventory at time pe-
iod t is below the maximum storage capacity, C p , while the con-
traint 10 ensures that the global storage capacity, C tot p , is not ex-
eeded. The duration a product can be is stored in inventory is lim-
ted by the constraint 10. 
 pt = I p,t−1 + 
∑ 
K ipt − S pt −W pt ∀ p ∈ P I i , t ∈ T I i (7)
i 













































































I pt ≤ C tot p ∀ t (9) 
 pt ≤
∑ t+ ζp 
θ= t+1 S pθ ∀ p, t (10) 
acklog constraints 
Constraint 11 penalises the amount of product p that was late
or delivery at time period t, pt . 
pt = πp p, t−1 + D pt − S pt ∀ p, t (11)
bjective function 
The objective function is to maximise proﬁt which is equal to
he difference between total sales and total operating costs. All
osts and prices are in relative monetary units (RMU). 




t∈ T I i 
( νp S pt − ρp I pt − δp pt 
−
∑ 
i ∈ I P p 
(
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